Sign In
Buy OPY
$99.90
+2.52 (+2.59%)
At Close: Jun 09, 2026
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
08:30am, Monday, 23'rd Feb 2026
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
08:00am, Monday, 23'rd Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-bas
Oppenheimer Channel Checks Bode Well for These 2 Cybersecurity Stocks
08:05am, Sunday, 22'nd Feb 2026
CrowdStrike continues to be the leader in the next-generation endpoint security space. SentinelOne appears to have had the biggest positive change in sentiment among channel partners.
Oppenheimer (NYSE:OPY) Share Price Passes Above 200-Day Moving Average – Should You Sell?
04:33am, Saturday, 21'st Feb 2026
Oppenheimer Holdings, Inc. (NYSE: OPY - Get Free Report)'s stock price passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $73.84 and traded as
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
09:00am, Thursday, 19'th Feb 2026
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical compan
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference
08:30am, Thursday, 19'th Feb 2026
Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sc
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
07:00am, Thursday, 19'th Feb 2026
BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
07:00am, Thursday, 19'th Feb 2026
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
08:00am, Wednesday, 18'th Feb 2026
HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for t
Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
08:00am, Wednesday, 18'th Feb 2026
MORRISTOWN, N.J., Feb. 18, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
07:01am, Wednesday, 18'th Feb 2026
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
06:59am, Wednesday, 18'th Feb 2026
WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
04:05pm, Tuesday, 17'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
08:00am, Tuesday, 17'th Feb 2026
DOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapie
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
08:00am, Tuesday, 17'th Feb 2026
TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammato
